A randomized, open label, controlled phase II study to evaluate safety, tolerability and immunogenicity after two different 13-valent pneumococcal conjugate vaccine formulations [pneumococcal 13-valent CRM197 vaccine conjugate +/- aluminium phosphate] in elderly subjects aged 65 years and older who are naive to previous 23vPS [23-valent pneumococcal polysaccharide vaccine] immunization

Trial Profile

A randomized, open label, controlled phase II study to evaluate safety, tolerability and immunogenicity after two different 13-valent pneumococcal conjugate vaccine formulations [pneumococcal 13-valent CRM197 vaccine conjugate +/- aluminium phosphate] in elderly subjects aged 65 years and older who are naive to previous 23vPS [23-valent pneumococcal polysaccharide vaccine] immunization

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2010

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics
  • Sponsors Wyeth
  • Most Recent Events

    • 24 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Aug 2010 Actual end date (Feb 2007) added as reported by ClinicalTrials.gov.
    • 23 Apr 2008 The expected completion date for this trial was 1 Dec 2007, according to CLinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top